Lvonescimab (** Generic name: Lvonescimab (brand names may vary by region and are subject to regulatory approval) **)

Immunotherapy

EU Experimental ES Not available 1 Clinical Trials

Description

Lvonescimab is an immunotherapy drug currently being studied in clinical trials for certain types of colorectal cancer. It is being investigated as a potential treatment option, often in combination with other therapies like chemotherapy and radiotherapy, for locally advanced rectal cancer. Specifically, trials are looking at its use in patients whose tumors are microsatellite stable (MSS) or have specific gene mutations (MLH1, MSH2, MSH6, PMS2). The goal of these trials is to see if adding Lvonescimab to standard treatment improves outcomes compared to standard treatment alone. It is not yet approved for use in colorectal cancer.

Mechanism of Action

Lvonescimab is designed to target specific proteins on cancer cells. By binding to these proteins, it helps the body's immune system recognize and attack the cancer cells. The specific proteins targeted by Lvonescimab are being characterized in clinical trials. It is being studied in combination with chemotherapy and radiotherapy to enhance the immune response against the tumor.

Side Effects

As Lvonescimab is still in clinical trials (Phase 2) The full range of potential side effects is still being evaluated. Side effects observed in trials so far may include those commonly associated with immunotherapy drugs and chemotherapy Such as fatigue Nausea Diarrhea Skin reactions And potential immune-related adverse events. Specific side effect data from the NCT06919510 trial are not available in this summary. Patients participating in trials are closely monitored for any adverse effects.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06919510 Phase 2
Not yet recruiting
A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Quick Info

Brand Name** Generic name: Lvonescimab (brand names may vary by region and are subject to regulatory approval) **
CategoryImmunotherapy
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Bevacizumab
Immunotherapy
512 trials
Cetuximab
Immunotherapy
364 trials
Pembrolizumab
Immunotherapy
196 trials
Panitumumab
Immunotherapy
126 trials
Nivolumab
Immunotherapy
116 trials
Tislelizumab
Immunotherapy
62 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.